ArticleInflammopharmacology2025
Intra-articular hexagonal boron nitride-hyaluronic acid composite hydrogels rebalance cytokine profiles and enhance extracellular matrix regeneration in a rabbit osteoarthritis model.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveOsteoarthritis (OA) is a chronic, degenerative joint disease characterized by cartilage breakdown, inflammation, and progressive loss of joint function, leading to significant disability and reduced quality of life. Current treatment strategies, including pharmacological agents and intra-articular (IA) injections such as corticosteroids and hyaluronic acid (HA), provide symptomatic relief but fail to halt disease progression or promote cartilage regeneration. This study investigates the therapeutic potential of novel injectable hybrid hydrogels composed of hexagonal boron nitride (hBN) nanoparticles (NP) and nanosheets (NS) combined with HA.
methodsA comprehensive in vivo evaluation was conducted using a rabbit OA model, incorporating biochemical, gene expression, histological, and Western blot analyses to assess the efficacy of these hybrid biomaterials. Cytotoxicity assays confirmed the biocompatibility of hBN-HA hybrid hydrogels at appropriate concentrations.
resultsOur results demonstrated that hybrid hydrogels significantly suppressed pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), while enhancing anti-inflammatory cytokine interleukin-10 (IL-10). Furthermore, key mediators involved in OA pathogenesis, such as vascular endothelial growth factor (VEGF) and semaphorin-3A (SEMA3A), were significantly downregulated in the treatment groups. Notably, NP hydrogels promoted collagen type II (COL2) synthesis and extracellular matrix restoration, while NS hydrogels exhibited superior anti-inflammatory effects. Histological analyses further confirmed improved cartilage integrity, with reduced fibrillation, inflammation, and vascular congestion in the NP and NS treatment groups compared to OA controls.
conclusionThe findings highlight the potential of hBN-HA hybrid hydrogels as a next-generation therapeutic strategy for OA, offering dual benefits of inflammation suppression and cartilage regeneration. Given their superior efficacy over HA alone, these biomaterials represent a promising translational approach that could be further explored for clinical applications in OA treatment.
Indexed as
Identifiers
40820067What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.